Remote Cardiac Safety Monitoring through the Lens of the FDA Biomarker Qualification Evidentiary Criteria Framework: A Case Study Analysis

Catching Cardiovascular Safety Signals Before They Become Attrition Events

Cardiovascular liabilities remain one of the leading reasons drug candidates fail during clinical development, and they don’t always show up where sponsors are looking. Early-stage trials often miss these signals entirely, with problems only becoming apparent once a drug is administered chronically over extended periods. A case study published in Digital Biomarkers, authored by Koneksa Health’s Elena Izmailova alongside collaborators from UNC’s Lineberger Comprehensive Cancer Center and the FDA’s Center for Drug Evaluation and Research, examines whether remote vital sign monitoring can close that detection gap.

How the Case Study Approaches the Problem

• The core opportunity: Vital sign data collected outside the clinic offers the potential for deeper physiological characterization of a drug candidate, along with earlier detection of safety signals that short, infrequent in-clinic visits are likely to miss.
• A regulatory lens, not just a technical one: Rather than evaluating remote cardiac monitoring purely as a data collection method, the authors apply the FDA’s biomarker qualification evidentiary criteria framework, the same standard used to assess laboratory and imaging biomarkers,  to determine what remote cardiac safety data would need to meet for regulatory credibility.
• A case study structure: The analysis is grounded in a specific case study, allowing the authors to walk through how the evidentiary criteria framework applies in practice, rather than staying at a purely theoretical level.
• Bridging drug safety and digital measurement: The paper connects two historically separate conversations, clinical pharmacovigilance and digital biomarker validation, treating remote cardiac monitoring as a formal safety tool that needs to meet the same evidentiary bar as any other biomarker used in regulatory decision-making.

Why This Matters for Drug Safety Programs

This case study makes a compelling argument for sponsors: remote, continuous cardiac monitoring isn’t just an operational convenience; it may be a more sensitive tool for catching cardiovascular liabilities early, provided it can meet the same evidentiary standard the FDA already applies to biomarker qualification. For programs where late-emerging cardiac safety signals have historically driven costly attrition, that earlier detection window is a meaningful advantage.

This is the same evidentiary rigor Koneksa Health brings to remote cardiac safety programs, applying established biomarker qualification frameworks to new, continuously collected data streams, so sponsors can trust what the data is telling them.

Reference: Izmailova ES, Wood WA, Liu Q, et al. Remote Cardiac Safety Monitoring through the Lens of the FDA Biomarker Qualification Evidentiary Criteria Framework: A Case Study Analysis. Digit Biomark. 2021;5(1):103-113. doi:10.1159/000515110. PMID: 34056520.